Role of glucosamine in development of diabetic neuropathy independent of the aldose reductase pathway

  title={Role of glucosamine in development of diabetic neuropathy independent of the aldose reductase pathway},
  author={Hiroki Mizukami and Sho Osonoi and Shizuka Takaku and Shin-ichiro Yamagishi and Saori Ogasawara and Kazunori Sango and Sookja K. Chung and Soroku Yagihashi},
  journal={Brain Communications},
Abstract Long-term metabolic aberrations contribute to the development of diabetic neuropathy but the precise mechanism or mechanisms remains elusive. We have previously shown that aldose reductase-deficient mice exhibit delayed onset and progression of neuropathy following induction of diabetes, suggesting a role both for downstream metabolites of this enzyme and also for other unrelated pathways. In this study, we have utilized comprehensive metabolomics analyses to identify potential… Expand

Figures from this paper

Inhibitory effects of xanthine oxidase inhibitor, topiroxostat, on development of neuropathy in db/db mice
The results revealed the beneficial effects of the xanthine oxidase inhibitor topiroxostat on neuropathy development in a mouse model of type 2 diabetes. Expand
Physiological and Pathological Roles of Aldose Reductase
Accumulating evidence suggests that inhibition of AR could modify the effects of cardiovascular disease, asthma, neuropathy, sepsis, and cancer; therefore, additional work is required to selectively target AR inhibitors to specific disease states. Expand
Aldose Reductase and the Polyol Pathway in Schwann Cells: Old and New Problems
Investigation of AR and the polyol pathway using immortalized Schwann cells established from normal and AR-deficient mice could shed light on the causal relationship between the metabolic abnormalities of Schwann Cells and discordance of axon-Schwann cell interplay in DPN, and led to the development of better therapeutic strategies against DPN. Expand
Collateral Glucose-Utlizing Pathwaya in Diabetic Polyneuropathy
Diabetic polyneuropathy (DPN) is the most common neuropathy manifested in diabetes. Symptoms include allodynia, pain, paralysis, and ulcer formation. There is currently no established radicalExpand
The cross‐talk between RAGE and DIAPH1 in neurological complications of diabetes: A review
It is suggested the cumulative effect of hyperglycaemia on RAGE–DIAPH1‐mediated signalling may be disruptive to axonal cytoskeletal organization and transport and is therefore likely to play a key role in pathogenesis of diabetic symmetrical axonal neuropathy. Expand
Silencing of PFKFB3 protects podocytes against high glucose-induced injury by inducing autophagy
Diabetic nephropathy (DN) is a diabetic complication that threatens the health of patients with diabetes. In addition, podocyte injury can lead to the occurrence of DN. The proteinExpand
Increased Oxidative Stress Underlies Abnormal Pain Threshold in a Normoglycemic Japanese Population
Urine 8-OHdG correlated positively with higher HbA1c levels and age in the normoglycemic population, and both inflammation and OS were correlated with elevated PINT scores in IFG subjects, suggesting that OS may be a major contributing factor to elevated Pint scores in a healthy Japanese population. Expand
Diabetic heart disease: A clinical update
It is imperative for every clinician involved in diabetes care to have a good understanding of the pathophysiology, clinical picture, diagnostic methods, and management of diabetes-related cardiac illness, to reduce morbidity and mortality among patients. Expand


Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor.
These findings implicate increased polyol pathway activity in the pathogenesis of diabetic neuropathy and treating diabetic Tg with an aldose reductase inhibitor for 8 weeks significantly prevented the accumulation of sorbitol, the decrease in MNCV and the increased myelinated fibre atrophy in diabetic TG. Expand
Aldose reductase, still a compelling target for diabetic neuropathy.
  • P. Oates
  • Medicine
  • Current drug targets
  • 2008
Evidence is now strong that the Osmotic Hypothesis and the nerve sorbitol endpoint were misleading, and this will lead to novel ARIs that will effectively and safely slow the progression of diabetic neuropathy. Expand
Glucotoxic Mechanisms and Related Therapeutic Approaches.
  • S. Yagihashi
  • Medicine
  • International review of neurobiology
  • 2016
In this review, the author summarizes the hitherto proposed theories on the pathogenesis of diabetic neuropathy related to glucose metabolism and future prospects for the effective treatment of neuropathy. Expand
Aldose Reductase–Deficient Mice Are Protected From Delayed Motor Nerve Conduction Velocity, Increased c-Jun NH2-Terminal Kinase Activation, Depletion of Reduced Glutathione, Increased Superoxide Accumulation, and DNA Damage
Increased polyol pathway flux through AR is a major contributing factor in the early signs of diabetic neuropathy, possibly through depletion of glutathione, increased superoxide accumulation, increased JNK activation, and DNA damage. Expand
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: effects on peripheral sensory nerve function, structure and molecular changes
The results suggest close association of neuropathy development with impaired signaling of insulin and GLP‐1 in diabetic rodents. Expand
The role of O‐GlcNAc signaling in the pathogenesis of diabetic retinopathy
The biology of the hexosamine biosynthesis pathway and O‐GlcNAc signaling is summarized, the current evidence for the role of O‐ Glc NAc signaling in diabetes and diabetic retinopathy is presented, and future directions for research on O‐glcNAC in the pathogenesis of diabetic retInopathy are discussed. Expand
Mechanism of diabetic neuropathy: Where are we now and where to go?
In conclusion, inhibition of single metabolic factors might not be sufficient for the treatment of neuropathy, but a combination of several inhibitors might be a promising approach to overcome this serious disorder. Expand
Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance.
The hypothesis that excessive flux through the hexosamine biosynthesis pathway mediates adverse regulatory and metabolic effects of hyperglycemia, specifically insulin resistance of glucose disposal, is supported. Expand
Excessive Hexosamines Block the Neuroprotective Effect of Insulin and Induce Apoptosis in Retinal Neurons*
  • Makoto Nakamura, A. Barber, +4 authors T. Gardner
  • Biology, Medicine
  • The Journal of Biological Chemistry
  • 2001
The results suggest that the excessive glucose flux through the HBP may direct retinal neurons to undergo apoptosis in a bimodal fashion; i.e. via perturbation of the neuroprotective effect of insulin mediated by Akt and via induction of apoptosis possibly by altered glycosylation of proteins. Expand
Activation of the Hexosamine Pathway Leads to Deterioration of Pancreatic β-Cell Function through the Induction of Oxidative Stress*
In isolated rat islets adenovirus-mediated overexpression of glutamine:fructose-6-phosphate amidotransferase (GFAT), the first and rate-limiting enzyme of the hexosamine pathway, leads to deterioration of β-cell function, which is similar to that found in diabetes. Expand